KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Cost of Revenue (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Cost of Revenue for 17 consecutive years, with $4.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue fell 14.86% to $4.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $13.9 billion, a 0.23% change, with the full-year FY2025 number at $13.9 billion, changed 0.23% from a year prior.
  • Cost of Revenue was $4.1 billion for Q4 2025 at Bristol Myers Squibb, up from $3.4 billion in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $4.8 billion in Q4 2024 to a low of $2.3 billion in Q3 2021.
  • A 5-year average of $2.9 billion and a median of $2.8 billion in 2021 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: decreased 22.42% in 2021, then soared 75.3% in 2024.
  • Bristol Myers Squibb's Cost of Revenue stood at $2.4 billion in 2021, then increased by 10.06% to $2.6 billion in 2022, then increased by 5.86% to $2.7 billion in 2023, then skyrocketed by 75.3% to $4.8 billion in 2024, then decreased by 14.86% to $4.1 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Cost of Revenue are $4.1 billion (Q4 2025), $3.4 billion (Q3 2025), and $3.4 billion (Q2 2025).